# FX-322 in Sensorineural Hearing Loss

> **NCT03616223** · PHASE1,PHASE2 · COMPLETED · sponsor: **Frequency Therapeutics** · enrollment: 23 (actual)

## Conditions studied

- Sensorineural Hearing Loss

## Interventions

- **DRUG:** FX-322
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03616223
- **Lead sponsor:** Frequency Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-03
- **Primary completion:** 2018-12-18
- **Final completion:** 2018-12-18
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2022-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03616223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03616223, "FX-322 in Sensorineural Hearing Loss". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03616223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*